TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31607677
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day plus rifaximin 1200 mg/day
Study: 25882778
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg every 12h for 4 weeks
Study: 19398277
Drug: Hydrocortisone (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (35 mg)
Study: 15470487
Drug: AB killer
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AB killer cell immunoglobulin-like receptor (KIR) phenotype in leukemic patients
Study: 15470487
Drug: AB killer
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AB killer cell immunoglobulin-like receptor (KIR) phenotype in healthy controls
Study: 11467911
Drug: Scopolamine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (intravenous injection)
Study: 11467911
Drug: Glycopyrrolate (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (intravenous injection)
Study: 7976460
Drug: Treatment program
Normalized name: ZO Skin Health Acne Prevention Plus Treatment Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment program (details not specified)
Study: 3371882
Drug: Intravenous hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hypertonic glucose (900 mOsmoles per liter) at 2 ml per min
Study: 31863865
Drug: Tofacitinib ECS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib ECS tablets (11 mg and 22 mg)
Study: 31863865
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg immediate-release formulation tablet
Study: 30181096
Drug: Nemonoxacin 500
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 500 mg once daily for 7-10 days
Study: 30181096
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once daily for 7-10 days
Study: 27389435
Drug: Short-6 mm
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-6 mm implant
Study: 27389435
Drug: Short-8 mm
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-8 mm implant with OSFE
Study: 27389435
Drug: Standard-10 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-10 mm implant with OSFE
Study: 25445508
Drug: Too Good
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Too Good for Drugs (TGFD) prevention program
Study: 16776793
Drug: Drug-specific computerized
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-specific computerized prescribing alerts (baseline)
Study: 14687170
Drug: OAF (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAF (Omeprazole 20 mg b.d., Amoxicillin 1000 mg b.d., Furazolidone 100 mg b.d. for 14 days)
Study: 14687170
Drug: OABF1 (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OABF1 (Omeprazole 20 mg b.d., Amoxicillin 1000 mg b.d., Furazolidone 100 mg b.d., Bismuth Subcitrate 240 mg b.d. for 14 days)
Study: 14687170
Drug: OABF2 (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OABF2 (Omeprazole 20 mg b.d., Amoxicillin 1000 mg b.d., Furazolidone 200 mg b.d., Bismuth Subcitrate 240 mg b.d. for 14 days)
Study: 25858519
Drug: Long-term omeprazole
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term omeprazole therapy
Study: 8951940
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine administration
Study: 8375123
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine administration
Study: 8404995
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate infusion at rates of 6 to 40 mumol kg‐1 min‐1
Study: 22309432
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion (control)
Study: 8404995
Drug: Overall rates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall rates of lactate appearance during lactate infusions
Study: 27348913
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group with tramadol sustained release tablets and amitriptyline, prescribed once a day for 4 weeks.
Study: 22687580
Drug: SAMe 800-1600
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe 800-1600 mg/d for 6 weeks
Study: 15764352
Drug: Legs covered
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Legs covered with towels during DHT (24 treatments)
Study: 15764352
Drug: Legs not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Legs not covered with towels during DHT (27 treatments)
Study: 12062853
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of metformin
Study: 9458021
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1.5 g twice daily with intravenous corticosteroids (5 mg/kg/day for 5 days followed by oral taper)
Study: 9458021
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 1-2 mg/kg/day with intravenous corticosteroids (5 mg/kg/day for 5 days followed by oral taper)
Study: 8574509
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of hymecromone
Study: 25422883
Drug: CP-601,927 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-601,927 2 mg twice daily
Study: 23312429
Drug: Naltrexone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone with MBSCT and enhanced medication management
Study: 23312429
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with MBSCT and enhanced medication management
Study: 23312429
Drug: Naltrexone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone with enhanced medication management only
Study: 23312429
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with enhanced medication management only
Study: 15306152
Drug: Monoclonal antiphospholipid
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antiphospholipid antibodies
Study: 15306152
Drug: Human sera
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human sera containing antiphospholipid antibodies
Study: 8431313
Drug: i.v. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. morphine
Study: 23419803
Drug: Contact lens
Normalized name: contact lens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact lens treatment
Study: 27183095
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) with donor lymphocyte infusion (DLI)
Study: 27183095
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) without donor lymphocyte infusion (DLI)
Study: 20444845
Drug: Immediate zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Immediate zoledronic acid (ZOL; 4 mg every 6 months)
Study: 17880755
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days
Study: 15270876
Drug: Temozolomide 150
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 150 mg m(‐2) on days 1‐5 every 28 days + IFN‐alpha 2b 10 MIU m(‐2) every other day (Group A)
Study: 15270876
Drug: Temozolomide 150
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 150 mg m(‐2) on days 1‐5 every 28 days + IFN‐alpha 2b fixed dose of 10 MIU every other day (Group B)
Study: 15270876
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who completed at least three cycles of therapy with partial or complete response
Study: 15270876
Drug: Major side
Approvals — FDA: no, EMA: no, PMDA: no
Description: Major side effects of treatment
Study: 11359431
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 microg inhaled plus 200 microg intranasal)
Study: 11359431
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg oral)
Study: 7954251
Drug: Glutamine-supplemented TPN
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-supplemented TPN (40 g L-alanyl-L-glutamine, 26 g glutamine)
Study: 29211298
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (3 courses)
Study: 23385035
Drug: IV rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV rocuronium 0.06 mg/kg
Study: 23602668
Drug: MEDI-534 vaccine
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-534 vaccine
Study: 8635377
Drug: Albuterol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (400 microg every 10 min)
Study: 8635377
Drug: Albuterol (ED50F)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (ED50F)
Study: 8635377
Drug: Albuterol and
Normalized name: Albuterol and cromolyn only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol and Fenoterol (Heart Rate)
Study: 30791125
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 40 μg/day
Study: 30791125
Drug: Anastrozole (ATZ)
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole (ATZ) 300 μg/day
Study: 29036427
Drug: Combined enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined enalapril 10 mg and folic acid 0.8 mg tablet
Study: 29036427
Drug: Enalapril 10 mg
Normalized name: enalapril 10 MG
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril 10 mg tablet alone
Study: 26871238
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 mg 0.5% hyperbaric bupivacaine + 0.1 mg morphine)
Study: 26871238
Drug: Fentanyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (5 mg 0.5% hyperbaric bupivacaine + 25 µg fentanyl)
Study: 26871238
Drug: Control (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5 mg 0.5% hyperbaric bupivacaine + physiologic saline)
Study: 23095095
Drug: Standard wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard wound care therapies
Study: 21060072
Drug: Ticagrelor 180-mg
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180-mg loading dose followed by 90 mg twice daily
Study: 21060072
Drug: Clopidogrel 300-mg
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300-mg loading dose followed by 75 mg daily
Study: 17425224
Drug: Gaboxadol 5
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 5 mg
Study: 8615705
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with lovastatin
Study: 1307655
Drug: Low-dose antacids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacids (Alugastrin and Alumag)
Study: 1307655
Drug: Low-dose antacids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacids and ranitidine
Study: 162669
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg t.i.d.
Study: 30985644
Drug: Trichlormethiazide 1
Normalized name: trichlormethiazide 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichlormethiazide 1 mg
Study: 20122589
Drug: Mapleson A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mapleson A system at 10 L/min
Study: 20122589
Drug: Mapleson D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mapleson D system at 10 L/min
Study: 20122589
Drug: Circle anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circle anesthesia system at 10 L/min
Study: 20122589
Drug: Mapleson A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mapleson A system at 5 L/min
Study: 20122589
Drug: Mapleson D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mapleson D system at 5 L/min
Study: 20122589
Drug: Circle anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circle anesthesia system at 5 L/min
Study: 17316865
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) spray
Study: 17316865
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) spray after crossover
Study: 1479161
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily (doubled dose after 4 weeks)
Study: 1479161
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg twice daily (doubled dose after 4 weeks)
Study: 1479161
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily (for refractory patients)
Study: 6464812
Drug: Assertion training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertion training treatment
Study: 30612858
Drug: Cligosiban 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban 100 mg once daily for 10 days
Study: 30612858
Drug: Cligosiban 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban 400 mg once daily for 10 days
Study: 30612858
Drug: Cligosiban 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban 800 mg once daily for 10 days
Study: 30612858
Drug: Cligosiban 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban 1200 mg once daily for 10 days
Study: 30612858
Drug: Cligosiban 2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban 2400 mg once daily for 10 days
Study: 24220616
Drug: Decitabine 20
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m² once daily for 5 days every 4 weeks (n = 242)
Study: 24220616
Drug: Treatment choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment choice (supportive care or cytarabine 20 mg/m² once daily for 10 days every 4 weeks; n = 243)
Study: 15641866
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg mirtazapine
Study: 16183813
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 3.3 g/100 kcal
Study: 16183813
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 3.0 g/100 kcal
Study: 16183813
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 2.7 g/100 kcal
Study: 16183813
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake greater than 2.7 g/100 kcal
Study: 12562576
Drug: Olanzapine +
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine + Reboxetine (4 mg/day)
Study: 31809349
Drug: Nanosecond Pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanosecond Pulsed Electric Field Treatment (NPS)
Study: 26560511
Drug: THC (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (0.75 mg twice daily in blocks 1-3 and 1.5 mg twice daily in blocks 4-6)
Study: 21831581
Drug: Intra-articular multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular multimodal drug injection
Study: 20141383
Drug: Recreation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreation therapy
Study: 17047021
Drug: T3 infusion
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 infusion
Study: 16398435
Drug: Local thermotherapy
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local thermotherapy with rabdosia liquid, starting from 1-2 months after operation, once tri-monthly for one year.
Study: 16398435
Drug: Intravesical perfusion
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical perfusion of mitomycin C, starting from 2 weeks after operation, once weekly for six times, thereafter once monthly for one year.
Study: 12196768
Drug: Dye-spray (0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dye-spray (0.1% indigo carmine used to coat the entire colon during withdrawal from the cecum)
Study: 2760254
Drug: Dilevalol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (single dose)
Study: 2760254
Drug: Dilevalol (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (chronic treatment)
Study: 23715873
Drug: Thiamine supplementation
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine supplementation (3 × 100 mg/day for 6 weeks)
Study: 20415525
Drug: Subcutaneous local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous local anesthesia (LA)
Study: 20415525
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional anesthesia (IVRA)
Study: 19672237
Drug: Galantamine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (8 mg daily for the 1st month, increasing to 16 mg daily; 6 patients received 24 mg from the 3rd month)
Study: 19672237
Drug: Galantamine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine with antipsychotic therapy (15 patients)
Study: 10691900
Drug: Oral challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenge with food rich in pseudoallergens
Study: 17094774
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate solution
Study: 2869210
Drug: Synthetic peptide
Normalized name: Copolymer I (synthetic peptide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic peptide vaccine (18-aminoacid E. coli heat-stable toxin and 26-aminoacid heat-labile toxin B subunit)
Study: 2869210
Drug: Synthetic peptide
Normalized name: Copolymer I (synthetic peptide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic peptide vaccine
Study: 30975047
Drug: Telehealth care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth care solution (Telekit)
Study: 24114969
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FP/SAL) 500/50 μg twice daily
Study: 22422352
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration (tablet)
Study: 22422352
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration (injection)
Study: 19744283
Drug: ab initio
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ab initio calcineurin inhibitor-based monotherapy immunosuppression
Study: 12117082
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate 0.2% ophthalmic suspension
Study: 10195537
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of mepivacaine 1% with 100 mg of tramadol (Group B)
Study: 10195537
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of mepivacaine 1% (Group A)
Study: 10195537
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of mepivacaine 1% with 2 mL of isotonic sodium chloride solution and 100 mg of tramadol i.v. (Group C)
Study: 7782256
Drug: Mupirocin calcium
Normalized name: Mupirocin Calcium
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin calcium ointment, intranasally bid for 5 days
Study: 7782256
Drug: Mupirocin calcium
Normalized name: Mupirocin Calcium
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin calcium ointment
Study: 7416559
Drug: Sublingual food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual food drops (egg, corn, milk, yeast)
Study: 31994511
Drug: Lurasidone (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (40, 80, 120 or 160 mg/d)
Study: 29233028
Drug: 50 µg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg liothyronine via nasogastric tube after gastric lavage, in the first 6 h of poisoning
Study: 29233028
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment of AlP poisoning (control group)
Study: 8839196
Drug: Pamidronate 180
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate 180 mg
Study: 12383144
Drug: Medication improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication improvement program (usual care with intervention)
Study: 8909433
Drug: BCAA (L-leucine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (L-leucine 12 g, L-isoleucine 8 g, L-valine 6.4 g daily)